Review Article

Neonatal Cholestasis: An Update

https://doi.org/10.47648/zhswmcj.2026.v0802.07

*Kadir S

ABSTRACT

Neonatal cholestasis (NC) is a group of disorders marked by impaired bile formation or flow, resulting in conjugated hyperbilirubinemia during the neonatal period. It affects about 1 in 2,500 live births and is a significant cause of infant morbidity and mortality. Early diagnosis is crucial as several causes are treatable, and delays can lead to progressive liver damage. Biliary atresia is the most common surgically correctable cause and a leading indication for pediatric liver transplantation. Advances in molecular genetics and next-generation sequencing are enhancing diagnosis. This review summarizes current concepts in epidemiology, pathophysiology, etiology, clinical manifestations, diagnosis, management, and recent advances in neonatal cholestasis.

Keywords: Neonatal cholestasis, conjugated hyperbilirubinemia, biliary atresia, neonatal liver disease, genetic cholestasis, pediatric hepatology, liver transplantation.

Received on : 20th May,2026 **Accepted on: 1st June,2026**

Introduction

Neonatal cholestasis is defined as impaired bile formation or bile flow resulting in retention of bile constituents within the liver and systemic circulation. Unlike unconjugated hyperbilirubinemia, cholestasis is always pathological and requires urgent evaluation. Persistent jaundice beyond two weeks of age accompanied by elevated direct bilirubin levels should prompt investigation for cholestatic liver disease.

The spectrum of neonatal cholestasis includes obstructive, infectious, metabolic, endocrine, genetic, and idiopathic causes. Timely diagnosis, particularly for biliary atresia, is vital as surgery before 60 days improves outcomes.

Epidemiology

The incidence of neonatal cholestasis is estimated at 1 in 2,000 to 1 in 5,000 live births. Biliary atresia accounts for 25–40% of cases. Recognition of genetic and metabolic disorders has increased due to advances in molecular diagnostics.

Pathophysiology

Cholestasis results from disruption of bile synthesis, secretion, or transport. Accumulation of bile acids, bilirubin, cholesterol, and other toxic metabolites within hepatocytes leads to progressive cellular injury, inflammation, fibrosis, and, eventually, cirrhosis.

Major mechanisms include:

1. Extrahepatic bile duct obstruction
2. Defects in hepatocellular transport proteins
3. Abnormal bile acid synthesis
4. Genetic abnormalities affecting canalicular secretion
5. Inflammatory injury to bile ducts

Address of Correspondence: : Prof. Dr. Sadika Kadir,Professor & Head of the Department of Paediatrics, Zainul Haque Sikder Women's medical College, dr.sadika_maruf@yahoo.com,01715550952.

Etiology

Table 1. Major Causes of Neonatal Cholestasis

Category	Common Disorders
Obstructive	Biliary atresia, choledochal cyst, inspissated bile syndrome
Genetic	Progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, alpha-1 antitrypsin deficiency
Metabolic	Galactosemia, tyrosinemia, Niemann-Pick disease, citrin deficiency
Infectious	Cytomegalovirus, toxoplasmosis, rubella, syphilis, hepatitis viruses
Endocrine	Congenital hypothyroidism, hypopituitarism
Toxic/Nutritional	Parenteral nutrition-associated cholestasis
Idiopathic	Idiopathic neonatal hepatitis

Clinical Presentation

The clinical manifestations vary according to the underlying etiology but commonly include:

- Persistent jaundice beyond 14 days
- Dark urine
- Pale or acholic stools
- Hepatomegaly
- Splenomegaly
- Failure to thrive
- Poor weight gain
- Coagulopathy
- Pruritus in chronic disease

Acholic stools remain one of the most important clues to biliary atresia.

Diagnostic Evaluation

Laboratory Investigations

Initial investigations should include:

- Total and direct bilirubin
- Liver enzymes (ALT, AST)
- Gamma-glutamyl transferase (GGT)
- Alkaline phosphatase
- Serum albumin
- Prothrombin time/INR
- Complete blood count
- Thyroid function tests

Metabolic Assessment

- Galactosemia screening
- Serum amino acids
- Urine organic acids
- Alpha-1 antitrypsin phenotype
- Tandem mass spectrometry

Infectious Screening

- TORCH studies
- CMV PCR
- Blood and urine cultures
- Hepatitis serology

Imaging

Abdominal Ultrasonography

Useful for identifying:

- Gallbladder abnormalities
- Triangular cord sign
- Choledochal cysts
- Structural liver disease

Hepatobiliary Scintigraphy (HIDA Scan)

Assesses bile excretion and may support diagnosis of biliary obstruction.

Liver Biopsy

Provides diagnostic accuracy approaching 90–95% for biliary atresia when interpreted by experienced pathologists.

Intraoperative Cholangiography

Remains the gold standard for diagnosing biliary atresia.

Figure 1. Diagnostic Algorithm for Neonatal Cholestasis

Persistent jaundice >14 days

↓

Measure total and direct bilirubin.

↓

Direct bilirubin elevated

↓
History + Physical examination
↓
Laboratory investigations
↓
Ultrasound evaluation
↓
Suspected biliary atresia?
→ Yes → Liver biopsy → Cholangiography → Kasai portoenterostomy
→ No → Metabolic, genetic, endocrine, and infectious evaluation
↓
Targeted treatment

Recent Advances in Diagnosis

Next-Generation Sequencing

Recent studies demonstrate that next-generation sequencing identifies a molecular diagnosis in approximately 25–50% of infants with previously unexplained cholestasis.

Applications include:

- Whole-exome sequencing
- Whole-genome sequencing
- Targeted cholestasis gene panels

Frequently identified genes include:

- ATP8B1
- ABCB11
- ABCB4
- JAG1
- NOTCH2
- TJP2

Biomarkers

Emerging biomarkers include:

- Matrix metalloproteinase-7 (MMP-7)
- Serum bile acid profiles
- Proteomic markers

MMP-7 has shown excellent diagnostic performance for distinguishing biliary atresia from other causes of neonatal cholestasis.

Management

Nutritional Support

Nutritional intervention is essential.

Recommendations include:

- Energy intake 120–150 kcal/kg/day
- Medium-chain triglyceride supplementation
- High-protein feeding

Fat-Soluble Vitamin Supplementation

Table 2. Vitamin Supplementation in Neonatal Cholestasis

Vitamin	Clinical Importance
Vitamin A	Vision and immune function
Vitamin D	Bone health
Vitamin E	Neurological protection
Vitamin K	Prevention of bleeding

Pharmacological Therapy

Commonly used medications include:

- Ursodeoxycholic acid
- Rifampicin
- Cholestyramine
- Phenobarbital (selected cases)

Disease-Specific Treatment

Table 3. Etiology-Specific Therapy

Disorder	Treatment
Biliary atresia	Kasai portoenterostomy
Galactosemia	Lactose-free diet
Tyrosinemia	Nitisinone
Hypothyroidism	Levothyroxine
CMV infection	Antiviral therapy

Surgical Management

Biliary Atresia

Kasai portoenterostomy remains the primary treatment.

Outcomes are best when surgery is performed before:

- 45–60 days of age

Delayed surgery is associated with:

- Progressive fibrosis
- Portal hypertension
- Increased transplantation risk

Liver Transplantation

Indications include:

- End-stage liver disease

- Failed Kasai procedure
- Progressive genetic cholestatic disorders
- Refractory pruritus
- Growth failure

Current pediatric liver transplantation survival rates exceed 85–90% at five years in experienced centers.

Future Perspectives

Emerging therapeutic approaches include:

- Gene therapy
- RNA-based therapeutics
- Precision medicine
- Novel bile acid modulators
- Stem cell therapies
- Artificial liver support systems

Expansion of newborn stool color card screening programs may facilitate earlier diagnosis of biliary atresia and improve outcomes.

Conclusion

Neonatal cholestasis remains a major diagnostic and therapeutic challenge in pediatric hepatology. Early identification, systematic evaluation, and timely intervention are crucial for improving outcomes. Advances in molecular diagnostics and precision medicine have significantly enhanced diagnostic accuracy and are expected to transform future management strategies. Multidisciplinary care involving neonatologists, pediatric hepatologists, surgeons, geneticists, nutritionists, and transplant teams remains essential for optimal patient outcomes.

References

1. Feldman AG, Sokol RJ. Recent developments in diagnostics and treatment of neonatal cholestasis. Semin Pediatr Surg. 2020;29(4):150945.
2. Fawaz R, Baumann U, Ekong U, Fischler B, Hadzić N, Mack CL, et al. Guidelines for the evaluation of cholestatic jaundice in infants. J Pediatr Gastroenterol Nutr. 2017;64(1):154-168.
3. Harpavat S, Finegold MJ, Karpen SJ. Patients with biliary atresia have elevated direct/conjugated bilirubin levels shortly after birth. Pediatrics. 2011;128(6):e1428-e1433.
4. Sokol RJ, Mack C, Narkewicz MR, Karrer FM. Pathogenesis and outcome of biliary atresia. Clin Liver Dis. 2003;7(4):829-848.
5. Bezerra JA, Wells RG, Mack CL, Karpen SJ, Hoofnagle JH, Doo E, et al. Biliary atresia: clinical and research challenges. Hepatology. 2018;68(3):1163-1173.
6. Baumann U, Knisely AS, Fischler B, Hadzic N, Mack CL. Neonatal cholestasis and biliary atresia. Lancet Child Adolesc Health. 2022;6(10):712-724.
7. Sundaram SS, Mack CL, Feldman AG, Sokol RJ. Biliary atresia: indications and timing of liver transplantation. Clin Liver Dis. 2017;21(2):313-328.
8. Kamath BM, Baker A, Houwen R, Todorova L, Kerkar N. Systematic review: the epidemiology, natural history and burden of Alagille syndrome. J Pediatr Gastroenterol Nutr. 2018;67(2):148-156.
9. Moyer V, Freese DK, Whitington PF, Olson AD, Brewer F, Colletti RB, et al. Guidelines for evaluation of cholestatic jaundice in infants. J Pediatr Gastroenterol Nutr. 2004;39(2):115-128.